Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $57,312.60 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 48,570 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $1.18, for a total transaction of $57,312.60. Following the sale, the insider owned 5,787,670 shares of the company’s stock, valued at $6,829,450.60. This trade represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $63,623.40.
• On Friday, November 7th, Bioventures 2014 L.P. Mpm sold 68,480 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total transaction of $76,012.80.
• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Bioventures 2014 L.P. Mpm sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total value of $124,318.48.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $208,072.00.

Werewolf Therapeutics Trading Down 1.0%

Werewolf Therapeutics stock opened at $0.92 on Friday. The firm has a 50 day moving average of $1.57 and a 200 day moving average of $1.33. The firm has a market capitalization of $44.57 million, a price-to-earnings ratio of -0.57 and a beta of 0.72. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.38. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. JMP Securities lowered their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Bank of America dropped their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday. Finally, Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. MPM Asset Management LLC increased its holdings in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the last quarter. MPM Bioimpact LLC boosted its stake in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after buying an additional 20,799 shares during the last quarter. Bank of America Corp DE grew its holdings in Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares in the last quarter. Vanguard Group Inc. increased its stake in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $409,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.